Drugs / CP-383
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07030257 | Aug 2025 → Aug 2028 expected | colorectal carcinoma, head and neck squamous cell carcinoma, malignant pancreatic neoplasm, non-small cell lung carcinoma +2 | Tasca Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CP-383 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07030257 ↗ |
| Action | Inhibit | “inhibiting pyrimidine synthesis in cancer cells” NCT07030257 ↗ |
| Route | Oral | “single daily oral capsule” NCT07030257 ↗ |